HRP20161686T1 - Pripravci i postupci za liječenje raka - Google Patents
Pripravci i postupci za liječenje raka Download PDFInfo
- Publication number
- HRP20161686T1 HRP20161686T1 HRP20161686TT HRP20161686T HRP20161686T1 HR P20161686 T1 HRP20161686 T1 HR P20161686T1 HR P20161686T T HRP20161686T T HR P20161686TT HR P20161686 T HRP20161686 T HR P20161686T HR P20161686 T1 HRP20161686 T1 HR P20161686T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- preparation
- use according
- inhibitor
- cellular energy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14838509P | 2009-01-29 | 2009-01-29 | |
| EP10736502.5A EP2391363B1 (en) | 2009-01-29 | 2010-01-29 | Compositions and methods for the treatment of cancer |
| PCT/US2010/022664 WO2010088564A2 (en) | 2009-01-29 | 2010-01-29 | Compositions and methods for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161686T1 true HRP20161686T1 (hr) | 2017-02-24 |
Family
ID=42396378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161686TT HRP20161686T1 (hr) | 2009-01-29 | 2010-01-29 | Pripravci i postupci za liječenje raka |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8022042B2 (enExample) |
| EP (1) | EP2391363B1 (enExample) |
| JP (2) | JP6068803B2 (enExample) |
| KR (1) | KR20110110355A (enExample) |
| CN (1) | CN102387801A (enExample) |
| AU (1) | AU2010208062B2 (enExample) |
| CA (2) | CA3024263A1 (enExample) |
| DK (1) | DK2391363T3 (enExample) |
| ES (1) | ES2607211T3 (enExample) |
| HR (1) | HRP20161686T1 (enExample) |
| HU (1) | HUE032389T2 (enExample) |
| IL (1) | IL214349A (enExample) |
| NZ (1) | NZ594434A (enExample) |
| PL (1) | PL2391363T3 (enExample) |
| PT (1) | PT2391363T (enExample) |
| SI (1) | SI2391363T1 (enExample) |
| WO (1) | WO2010088564A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8324175B2 (en) | 2006-02-16 | 2012-12-04 | Young Hee Ko | Compositions and methods for the treatment of cancer |
| US9211377B2 (en) | 2009-07-30 | 2015-12-15 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| CN103610671A (zh) * | 2013-12-10 | 2014-03-05 | 江苏长泰药业有限公司 | 丙酮酸药物组成及其在制备治疗肺癌药物中的用途 |
| EP3293167A1 (en) | 2016-09-09 | 2018-03-14 | Université Catholique De Louvain | [18f]-labelled lactate derivative as pet radiotracer |
| US10434113B2 (en) | 2016-12-16 | 2019-10-08 | The Charlotte Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| US10245235B2 (en) | 2016-12-16 | 2019-04-02 | The Charlotte-Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| KR102623283B1 (ko) * | 2017-03-15 | 2024-01-11 | 루넬라 바이오테크 인코포레이티드 | 미토리보신: 암 세포, 박테리아, 및 병원성 효모를 표적으로 하는 미토콘드리아 기반의 치료제 |
| EP4504152A2 (en) * | 2022-04-06 | 2025-02-12 | Young Hee Ko | Liquid-dispersible halopyruvate formulations and associated methods |
| CN116375769B (zh) * | 2023-03-10 | 2024-12-03 | 云南贵金属实验室有限公司 | 一种双靶点Pt(Ⅳ)抗癌前药及其制备方法和用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3360633D1 (en) | 1982-02-12 | 1985-10-03 | Unitika Ltd | Anti-cancer device |
| US5800820A (en) | 1989-01-10 | 1998-09-01 | Repligen Corporation | Methods and compositions for treatment of angiogenic diseases |
| US5759837A (en) | 1989-01-17 | 1998-06-02 | John Hopkins University | Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway |
| US5284786A (en) * | 1992-08-14 | 1994-02-08 | National Semiconductor Corporation | Method of making a split floating gate EEPROM cell |
| US5854067A (en) | 1996-01-19 | 1998-12-29 | Board Of Regents, The University Of Texas System | Hexokinase inhibitors |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| US6031000A (en) | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| US6284786B1 (en) | 1999-02-16 | 2001-09-04 | The Center For The Improvement Of Human Functioning, Int'l., Inc. | Treatment of cancer using lipoic acid in combination with ascorbic acid |
| US20020006915A1 (en) | 2000-02-15 | 2002-01-17 | Mack Strong Vivian E. | Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation |
| US6448030B1 (en) | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
| WO2001068667A1 (en) | 2000-03-14 | 2001-09-20 | The Johns Hopkins University School Of Medicine | Arrest of proliferation of highly glycolytic tumors |
| US6670330B1 (en) * | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
| AU2002233916A1 (en) | 2000-08-03 | 2002-04-29 | Albert Einstein College Of Medicine | Isocitrate lyase enzyme from mycobacterium tuberculosis and inhibitory agents to combat persistent infection |
| US7381713B2 (en) | 2000-12-04 | 2008-06-03 | Sioan-Kettering Institute For Cancer Research | Treatment of cancer by reduction of intracellular energy and pyrimidines |
| US7547673B2 (en) * | 2001-09-13 | 2009-06-16 | The Johns Hopkins University | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
| EP1526865A4 (en) | 2002-08-05 | 2009-09-02 | Mirus Bio Corp | COMPOUNDS FOR TARGETING HEPATIC CELLS |
| CA2498130A1 (en) | 2002-09-05 | 2004-03-18 | Invitrogen Corporation | Compositions and methods for synthesizing nucleic acids |
| US20040229826A1 (en) * | 2002-12-12 | 2004-11-18 | Larry Norton | Dose-dense & sequential adjuvant cancer chemotherapy |
| US6979675B2 (en) | 2003-01-10 | 2005-12-27 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
| EP1610778A4 (en) | 2003-01-17 | 2006-05-31 | Threshold Pharmaceuticals Inc | TREATMENT OF BENIGNER PROSTATE HYPERPLASIA |
| US20060172953A1 (en) | 2003-01-17 | 2006-08-03 | Threshold Pharmaceuticals Inc. | Treatment of benign prostatic hyperplasia using energolytic agents |
| AU2005274165A1 (en) * | 2004-07-28 | 2006-02-23 | Board Of Regents, The University Of Texas System | 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| JP2008540566A (ja) * | 2005-05-12 | 2008-11-20 | スレッシュオールド ファーマシューティカルズ， インコーポレイテッド | ２−デオキシグルコースを用いたがんの処置 |
| US7754693B2 (en) * | 2006-02-16 | 2010-07-13 | Young Hee Ko | Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer |
| EP2114413B1 (en) | 2006-12-18 | 2014-10-22 | The Johns Hopkins University | Therapeutics for treating cancer using 3-bromopyruvate |
-
2010
- 2010-01-29 DK DK10736502.5T patent/DK2391363T3/en active
- 2010-01-29 NZ NZ594434A patent/NZ594434A/en not_active Application Discontinuation
- 2010-01-29 PL PL10736502T patent/PL2391363T3/pl unknown
- 2010-01-29 US US12/697,169 patent/US8022042B2/en active Active
- 2010-01-29 PT PT107365025T patent/PT2391363T/pt unknown
- 2010-01-29 CA CA3024263A patent/CA3024263A1/en not_active Abandoned
- 2010-01-29 SI SI201031357A patent/SI2391363T1/sl unknown
- 2010-01-29 AU AU2010208062A patent/AU2010208062B2/en active Active
- 2010-01-29 EP EP10736502.5A patent/EP2391363B1/en active Active
- 2010-01-29 ES ES10736502.5T patent/ES2607211T3/es active Active
- 2010-01-29 HR HRP20161686TT patent/HRP20161686T1/hr unknown
- 2010-01-29 KR KR1020117019808A patent/KR20110110355A/ko not_active Ceased
- 2010-01-29 WO PCT/US2010/022664 patent/WO2010088564A2/en not_active Ceased
- 2010-01-29 CA CA2750944A patent/CA2750944C/en active Active
- 2010-01-29 JP JP2011548359A patent/JP6068803B2/ja active Active
- 2010-01-29 CN CN2010800121947A patent/CN102387801A/zh active Pending
- 2010-01-29 HU HUE10736502A patent/HUE032389T2/en unknown
-
2011
- 2011-07-28 IL IL214349A patent/IL214349A/en active IP Right Grant
-
2015
- 2015-06-10 JP JP2015117604A patent/JP2015180680A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2750944A1 (en) | 2010-08-05 |
| EP2391363B1 (en) | 2016-09-28 |
| CA3024263A1 (en) | 2010-08-05 |
| US20100197612A1 (en) | 2010-08-05 |
| ES2607211T3 (es) | 2017-03-29 |
| JP2015180680A (ja) | 2015-10-15 |
| JP6068803B2 (ja) | 2017-01-25 |
| WO2010088564A2 (en) | 2010-08-05 |
| EP2391363A2 (en) | 2011-12-07 |
| AU2010208062A1 (en) | 2011-08-18 |
| PL2391363T3 (pl) | 2017-03-31 |
| CN102387801A (zh) | 2012-03-21 |
| US8022042B2 (en) | 2011-09-20 |
| SI2391363T1 (sl) | 2017-01-31 |
| IL214349A0 (en) | 2011-09-27 |
| HUE032389T2 (en) | 2017-09-28 |
| DK2391363T3 (en) | 2017-01-16 |
| IL214349A (en) | 2015-02-26 |
| EP2391363A4 (en) | 2012-09-19 |
| AU2010208062B2 (en) | 2014-07-24 |
| WO2010088564A3 (en) | 2010-12-29 |
| CA2750944C (en) | 2019-01-08 |
| KR20110110355A (ko) | 2011-10-06 |
| JP2012516358A (ja) | 2012-07-19 |
| NZ594434A (en) | 2014-11-28 |
| PT2391363T (pt) | 2016-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161686T1 (hr) | Pripravci i postupci za liječenje raka | |
| JP2012516358A5 (enExample) | ||
| AU2002352105B2 (en) | Platinum derivative pharmaceutical formulations | |
| EA021059B1 (ru) | Фармацевтический состав | |
| CA2645037C (en) | Pharmaceuticals containing fluoroquinolones | |
| IE80461B1 (en) | New compositions containing taxane derivatives | |
| JP2005002123A5 (enExample) | ||
| JPWO1999002158A1 (ja) | ４，５−エポキシモルヒナン誘導体を含有する安定な医薬品組成物 | |
| RU2013138672A (ru) | Способ, композиция и набор для чистки кишечника | |
| EP4100019A1 (en) | Method for treating coronavirus infections | |
| WO2015038431A1 (en) | Stable compositions of peptide epoxy ketones | |
| RU2013130224A (ru) | Фармацевтические композиции | |
| BR112012003907A2 (pt) | composições farmacêuticas para prevenção ou tratamento da osteoporose, a ser adminstrada uma vez por mês | |
| JP2019526634A5 (enExample) | ||
| JP2005015368A (ja) | プラノプロフェン含有水性液剤の安定化方法 | |
| ES3024479T3 (en) | Managing nephrogenic diabetes insipidus | |
| WO2016024369A1 (ja) | がん治療用医薬組成物 | |
| JP2015534985A5 (enExample) | ||
| JP6980665B2 (ja) | ペメトレキセド製剤 | |
| ES3024364T3 (en) | Method for preventing precipitation of injectable solution containing p-boronophenylalanine | |
| RU2016115374A (ru) | Фармацевтические композиции, содержащие антибактериальные агенты | |
| WO2013062050A1 (ja) | ゲムシタビン水溶液製剤 | |
| JP2018168088A (ja) | ボルテゾミブ液状製剤 | |
| CN111511349B (zh) | 包含伊立替康或其药剂学上可接受的盐的用于口服给药的药剂学组合物 | |
| RU2016115376A (ru) | Фармацевтические композиции, содержащие антибактериальные агенты |